Phosphorus Announces Launch of Genetic Testing SaaS Platform, Elements
The company’s HIPAA-compliant, cloud-based software suite is an end-to-end solution for in-house genetic testing that provides complete administrative functionality through all stages of the clinical workflow.
Phosphorus, a computational genomics company based in New York, announced today the formal launch of its Elements software suite to power diagnostic genetic testing for laboratories, hospital networks, and other health centers. The platform consists of 6 distinct modules to manage logistics, accessioning, lab tracking, bioinformatics, variant curation, and reporting. The suite is one component of a broader in-house testing partnership offered by Phosphorus, which also includes predesigned sequencing assays, reimbursement consulting, and operational assistance.
Phosphorus has designed Elements software for the modern clinician, allowing clinical partners worldwide to benefit from increased agility and adaptability. To that extent, the software is built with specific considerations in mind, including full HIPAA compliance, scalability, security, intuitive dashboards, and highly customizable algorithms, forms, and workflows. In addition, Elements easily integrates with existing workplace systems, such as legacy variant data annotations, EMR systems, and more. All product highlights are offered alongside outstanding and responsive customer service, from guidance on SOPs to billing assistance and beyond.
SaaS solutions to in-house genetic testing are relatively new, having appeared concurrently with the dramatic decrease of genome sequencing costs over the last decade. Phosphorus’ entry into the SaaS market is focused on the promise of a superior user experience packaged in an out-of-the-box, ready-to-use clinical tool for the genetic testing process. The Elements suite is being formally debuted at the American Society of Human Genetics (ASHG) Annual Meeting in Orlando, Florida today, October 19.
“Implementation of a Precision Medicine strategy is still a huge challenge for most hospitals and health systems,” said Alexander Bisignano, co-founder and CEO of Phosphorus. “A strong genomics core at the center of any strategy is really important, and with our Elements software, the challenges and costs of bringing clinical testing in-house are significantly reduced.”
Alongside Elements software, Phosphorus offers a catalogue of diagnostic genetic tests in a variety of specialty areas, all designed for complete compatibility with the newly-released Elements software platform. The affordable diagnostic tests are built upon expert-curated panels, powerful data analytics, a simple testing workflow, and rigorous variant interpretations to ensure the most accurate results for patients. “Our portfolio of diagnostic products, paired with Phosphorus Elements software, is the first end-to-end solution enabling laboratories and medical centers to easily build and expand their precision medicine capabilities,” Bisignano stated.
Learn more about Phosphorus Elements software at the American Society of Human Genetics Annual Meeting in Orlando, Florida at booth #1005. View the company’s research poster presentation, “Challenges Associated with Increasing the Predictive Power of AMH in Controlled Ovarian Stimulation” on Thursday, October 19, 2017 3-4 PM in the Exhibit Hall (poster #476T).
Phosphorus is a computational genomics company with the vision to create a world where every healthcare decision is optimized with genomics. Headquartered in New York City, Phosphorus offers clinical genetic tests in a range of clinical areas from its CLIA-certified laboratory. The company also develops powerful software that enables labs around the world to deliver the most advanced genetic tests. Phosphorus’ active research and development program has an initial focus on decoding the genetic causes of infertility and inherited cardiovascular disease. With a team of experts in computational biology and computer science, Phosphorus is building a data network that will help providers, researchers and patients around the world better understand and harness the power of the human genome. For more information visit: www.phosphorus.com and @phosphorus.